| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H19Cl2FN4O4S |
| Molecular Weight | 513.369 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(=O)(=O)C1=CC(F)=C(C=C1)N2C=C(Cl)C(OC3CCN(CC3)C4=NC=C(Cl)C=N4)=CC2=O
InChI
InChIKey=OGIAVRWXUPYGGC-UHFFFAOYSA-N
InChI=1S/C21H19Cl2FN4O4S/c1-33(30,31)15-2-3-18(17(24)8-15)28-12-16(23)19(9-20(28)29)32-14-4-6-27(7-5-14)21-25-10-13(22)11-26-21/h2-3,8-12,14H,4-7H2,1H3
| Molecular Formula | C21H19Cl2FN4O4S |
| Molecular Weight | 513.369 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Bristol-Myers Squibb was developing BMS 903452, a GPR119 agonist, for the treatment of patients with type 2 diabetes mellitus. G-protein-coupled receptor 119 (GPR119) is expressed predominantly in pancreatic β-cells and in enteroendocrine cells in the gastrointestinal tract. GPR119 agonists have been shown to stimulate glucose-dependent insulin release by direct action in the pancreas and to promote the secretion of the incretin GLP-1 by action in the gastrointestinal tract. BMS 903452 participated in phase I clinical trials in healthy subjects and in patients with type 2 diabetes mellitus to evaluate the safety, tolerability, and effect on blood glucose control. However, further information is not available.
